CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

Cancer Immunology, Immunotherapy

Volumn 64, Issue 1, 2015, Pages 105-112

  Calabrò, Luana ^a   Ceresoli, Giovanni Luca ^b   di Pietro, Alessandra ^c   Cutaia, Ornella ^a   Morra, Aldo ^d   Ibrahim, Ramy ^e   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

^c MEDIMMUNE   (United States)

^d Euganea Medica Diagnostic Centre   (Italy)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Anti CTLA4 mAb; Immunotherapy; Mesothelioma; NIBIT 2013; Tremelimumab

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; TICILIMUMAB;

ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; MESOTHELIOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84925021172     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1609-9     Document Type: Review

References (43)

1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716–724
2. Ceresoli GL, Gridelli C, Santoro A (2007) Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 12:850–863
3. Datta A, Smith R, Fiorentino F, Treasure T (2014) Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax 69:194–197
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
5. Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756–763
6. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509–2515
7. Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P (2013) Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 14:543–551
8. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24–32
9. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698–1704
10. Krug LM, Kindler H, Calvert H, VANTAGE 014 et al (2011) Vorinostat in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 47(Suppl 2):2–3
11. Ceresoli GL, Zucali PA (2012) Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin Investig Drugs 21:833–844
12. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A (2011) Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72:73–77
13. Busacca S, Sheaff M, Arthur K, Gray SG, O’Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 227:200–208
14. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5(208):208ra147
15. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104–1111
16. Eggermont A, Kroemer G, Zitvogel L (2013) Immunotherapy and the concept of a clinical cure. Eur J Cancer 49:2965–2967
17. Calabrò L, Danielli R, Sigalotti L, Maio M (2010) Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 37(5):460–467
18. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054
19. Calabrò L, Maio M (2014) Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease? OncoImmunology 3:e27482
20. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immunotherapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
21. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260
22. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M (2012) Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 75(3):360–367
23. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62:1021–1028
24. Calabrò L, Maio M (2014) Biomarkers for immune checkpoint inhibitors. Lancet Oncol 15(1):e1–e2
25. Calabro’ L, Morra A, Fonsatti F, Cutaia O, Fazio C, Danielli D, Giannarelli D, Altomonte M, Di Giacomo AM, Maio M (2014) A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol 32:5s (suppl: abstr 7531)
26. Maeda M, Nishimura Y, Kumagai N, Hayashi H, Hatayama T, Katoh M, Miyahara N, Yamamoto S, Hirastuka J, Otsuki T (2010) Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 7(4):268–278
27. Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS (2011) Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 60(11):1509–1527
28. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622
29. Kumagai-Takei N, Maeda M, Chen Y, Matsuzaki H, Lee S, Nishimura Y, Hiratsuka J, Otsuki T (2011) Asbestos induces reduction of tumor immunity. Clin Dev Immunol 2011:481439. doi:10.1155/2011/481439
30. Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ (1996) Malignant pleural mesothelioma: radiologic–pathologic correlation. Radiographics 16:613–644
31. Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging and PET. Radiographics 24:105–119
32. Leung AN, Miller NL, Miller RR (1990) CT in differential diagnosis of diffuse pleural disease. AJR 154:487–492
33. Boiselle PM, Patz EF Jr, Vining DJ, Weissleder R, Shepard JA, McLoud TC (1998) Imaging of mediastinal limph nodes: CT, MR and FDG-PET. Radiographics 18:1061–1069
34. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C (1999) Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR 172:1039–1047
35. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP (2004) Inadequacy of the RECIST criteria for the evaluation of response in patient with malignant pleural mesothelioma. Lung Cancer 43(1):63–69
36. Armato SG 3rd, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H (2006) Variability in mesothelioma tumor response classification. AJR 186:1000–1006
37. Mullard A (2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12:489–492
38. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133
39. Chen YB, Mu CY, Huang JA (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98(6):751–755
40. Pardoll D (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
41. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res [Epub ahead of print]
42. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
43. Sigalotti L, Fratta E, Coral S, Maio M (2014) Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 142(3):339–350. doi:10.1016/j.pharmthera.2013.12.015